Five Philly Gene Therapy Companies You Should Know

Published on : Published by : Bryan Spiegelberg, Ph.D.

More than 40 cell and gene therapy companies call Philadelphia home. Their work is facilitated by academic/industrial partnerships with world-class scientists at Children’s Hospital of Philadelphia (CHOP), Temple University, Drexel University, and University of Pennsylvania. Led by Wilson, UPenn’s Gene Therapy Program has been a particularly strong catalyst of the growth that led to $3 billion in investment in cell and gene therapies (CGT) in 2021. 

Global Cell and Gene Therapy Company Miltenyi Biotec is Expanding its Operations in Maryland 

Published on : Published by : BioBuzz Media

BALTIMORE, MD (March 15, 2022) — Global biotechnology business Miltenyi Biotec is expanding its operations in Maryland and transferring its North American headquarters to Gaithersburg. The company is working on expanding its 1201 Clopper Road facility to support additional manufacturing, research and development, quality assurance, and more. Miltenyi Biotec plans to add 130 new full-time jobs in Maryland, giving it a total of 300 employees in the state by the end of the year.
“By selecting Maryland for its North American headquarters, Miltenyi Biotec will help us continue growing our industry and further our efforts in remaining one of the top 10 life sciences clusters in the nation,” said Governor Larry Hogan. “We welcome the company’s continued investment in Montgomery County and look forward to supporting their efforts in Maryland and across the globe.”
This is not the company’s first investment in Maryland in recent years. In 2014, Miltenyi Biotec acquired Gaithersburg’s lentiviral vector manufacturing company Lentigen Technology Inc., which develops and commercializes therapeutics for stem cell therapies and oncology. In 2017, the company acquired Living Pharma, Inc., a startup of the University of Maryland, Baltimore that develops personalized cell therapy for targeted individuals’ cancers and diseases. Both became part…

NF2 BioSolutions Is Accelerating Research to Cure a Rare Tumor Disease

Collage of individuals with NF2 with text saying "I Need a Cure" and NF2 BioSolutions Logo
Published on : Published by : Sarah Ellinwood

Neurofibromatosis type II, also known as NF2, is a rare disease caused by a mutation in the NF2 gene, whose protein product, “Merlin”, plays a key role in managing cell proliferation. In Merlin’s absence, cells will grow unchecked, forming benign tumors throughout the body.

American Gene Technologies says clinical trial shows increases in immunity against HIV

Published on : Published by : BioBuzz Media

ROCKVILLE, Md. (7News) — There’s more good news in the fight to cure HIV.
American Gene Technologies says its clinical trial has resulted in more patients with substantial increases in virus-specific T-cells with immunity against HIV.
Progress in HIV cure: AGT hopes to have a ‘functionally cured patient by next summer’
“Now the question will be the very final step when we withdraw antiretroviral therapy, will it behave as we expect which is to take over viral suppression and these patients will not need to go back on their antiretroviral therapy again,” said CEO Jeff Galvin.
He says that process would start by the end of March at the earliest and he hopes to find out how successful it is by June.

5 Top Maryland Cell and Gene Therapy Companies Actively Searching for Talent

Two businesspeople shaking hands, with logos of Kite Pharma, NextCure, Arcellx, NexImmune, and MaxCyte
Published on : Published by : Steven Surdez

The BHCR cluster, in particular, includes a host of emerging and established cell and gene therapy companies, as well one of the deepest and most advanced biomanufacturing infrastructures in the U.S. While the cell and gene therapy industry still faces challenges like high manufacturing costs, high cost per dose to patients and complex supply chain issues, this sector remains very healthy and is continuing to grow rapidly in our region and globally.

NeuExcell Therapeutics, Inc. Signs Lease with The Discovery Labs to Establish Corporate Headquarters in the Philadelphia Region

NeuExcell Therapeutics Logo
Published on : Published by : BioBuzz Media

NeuExcell Therapeutics, Inc., a preclinical gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases, today announced the signing of a lease with The Discovery Labs in King of Prussia, PA. This lease sets the stage for NeuExcell to establish their long-term corporate headquarters in the heart of Philadelphia’s Cellicon Valley region and enables the company to build a world-class team tapping into the veteran cell and gene therapy talent in Greater Philadelphia.

REGENXBIO Closes $370M+ Gene Therapy Eye Care Collaboration Agreement with AbbVie for Wet AMD and Diabetic Retinopathy

Published on : Published by : BioBuzz Media

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

REGENXBIO and Solid Biosciences Take Aim at Rare Diseases with AAV Gene Therapies via New Pathway Development Consortium

REGENXBIO Logo
Published on : Published by : Alex Keown

Rare disease specialist REGENXBIO is partnering with Solid Biosciences to advance AAV gene therapies for rare diseases through an accelerated approval pathway with the U.S. Food and Drug Administration.

Spark signs gene therapy licensing deal valued at up to $328.5M

Published on : Published by : BioBuzz Media

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, and CombiGene AB (‘CombiGene’) today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark.